Drug Profile
Research programme: sulphostin - Nippon Kayaku
Latest Information Update: 22 Feb 2010
Price :
$50
*
At a glance
- Originator Nippon Kayaku
- Class
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 23 Nov 2005 Preclinical trials in Undefined in Japan (unspecified route)